Identifying and understanding the key determinants of effective anti-tumor immunity using combined experimental and computational approaches

Immunogenomics

We employ bulk and single-cell genomic approaches to uncover interactions between somatic alterations and immune infiltration, and to dissect the tumor-immune microenvironment.

Patient-derived models

The successful development of novel immunotherapeutics will depend in large part on enhancing our understanding of human tumor immunology using patient-derived model systems. Renal cell carcinoma (RCC) is an immunotherapy-responsive cancer that can serve as a model system for understanding key anti-tumor immune determinants in a human system.

Clinical translation

Collaboratively translating our laboratory findings into early “signal-finding”, investigator-initiated phase 1 clinical trials to advance care for patients with advanced cancer.